Literature DB >> 20164245

Low serum testosterone levels are associated with increased risk of mortality in a population-based cohort of men aged 20-79.

Robin Haring1, Henry Völzke, Antje Steveling, Alexander Krebs, Stephan B Felix, Christof Schöfl, Marcus Dörr, Matthias Nauck, Henri Wallaschofski.   

Abstract

AIMS: Although the association of low serum testosterone levels with mortality has gained strength in recent research, there are few population-based studies on this issue. This study examined whether low serum testosterone levels are a risk factor for all-cause or cause-specific mortality in a population-based sample of men aged 20-79. METHODS AND
RESULTS: We used data from 1954 men recruited for the prospective population-based Study of Health in Pomerania, with measured serum testosterone levels at baseline and 195 deaths during an average 7.2-year follow-up. A total serum testosterone level of less than 8.7 nmol/L (250 ng/dL) was classified as low. The relationships of low serum testosterone levels with all-cause and cause-specific mortality were analysed by Cox proportional hazards regression models. Men with low serum testosterone levels had a significantly higher mortality from all causes than men with higher serum testosterone levels (HR 2.24; 95% CI 1.41-3.57). After adjusting for waist circumference, smoking habits, high-risk alcohol use, physical activity, renal insufficiency, and levels of dehydroepiandrosterone sulfate, low serum testosterone levels continued to be associated with increased mortality (HR 2.32; 95% CI 1.38-3.89). In cause-specific analyses, low serum testosterone levels predicted increased risk of death from cardiovascular disease (CVD) (HR 2.56; 95% CI 1.15-6.52) and cancer (HR 3.46; 95% CI 1.68-6.68), but not from respiratory diseases or other causes.
CONCLUSION: Low serum testosterone levels were associated with an increased risk of all-cause mortality independent of numerous risk factors. As serum testosterone levels are inversely related to mortality due to CVD and cancer, it may be used as a predictive marker.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20164245     DOI: 10.1093/eurheartj/ehq009

Source DB:  PubMed          Journal:  Eur Heart J        ISSN: 0195-668X            Impact factor:   29.983


  84 in total

1.  Relation between sex hormone concentrations, peripheral arterial disease, and change in ankle-brachial index: findings from the Framingham Heart Study.

Authors:  Robin Haring; Thomas G Travison; Shalender Bhasin; Ramachandran S Vasan; Henri Wallaschofski; Maithili N Davda; Andrea Coviello; Joanne M Murabito
Journal:  J Clin Endocrinol Metab       Date:  2011-09-21       Impact factor: 5.958

2.  Effects of substitutive therapy on right ventricular systolic and diastolic functions in patients with idiopathic hypogonadotropic hypogonadism.

Authors:  Y T Yaylali; G Fidan Yaylali; F Akin; I Susam; M Bastemir
Journal:  J Endocrinol Invest       Date:  2010-09-02       Impact factor: 4.256

3.  Clinical correlates of sex steroids and gonadotropins in men over the late adulthood: the Framingham Heart Study.

Authors:  R Haring; V Xanthakis; A Coviello; L Sullivan; S Bhasin; H Wallaschofski; J M Murabito; R S Vasan
Journal:  Int J Androl       Date:  2012-05-29

4.  Low total testosterone levels are associated with the metabolic syndrome in elderly men: the role of body weight, lipids, insulin resistance, and inflammation; the Ikaria study.

Authors:  Christina Chrysohoou; Demosthenes Panagiotakos; Christos Pitsavos; Gerasimos Siasos; Evangelos Oikonomou; John Varlas; Athanasios Patialiakas; George Lazaros; Theodora Psaltopoulou; Marina Zaromitidou; Polina Kourkouti; Dimitris Tousoulis; Christodoulos Stefanadis
Journal:  Rev Diabet Stud       Date:  2013-05-10

Review 5.  Clinical review: Endogenous testosterone and mortality in men: a systematic review and meta-analysis.

Authors:  Andre B Araujo; Julia M Dixon; Elizabeth A Suarez; M Hassan Murad; Lin T Guey; Gary A Wittert
Journal:  J Clin Endocrinol Metab       Date:  2011-08-03       Impact factor: 5.958

6.  An update on male hypogonadism therapy.

Authors:  Prasanth Surampudi; Ronald S Swerdloff; Christina Wang
Journal:  Expert Opin Pharmacother       Date:  2014-04-23       Impact factor: 3.889

Review 7.  Testosterone Replacement Therapy and Mortality in Older Men.

Authors:  G I Hackett
Journal:  Drug Saf       Date:  2016-02       Impact factor: 5.606

8.  Lower Circulating Androgens Are Associated with Overall Cancer Risk and Prostate Cancer Risk in Men Aged 25-84 Years from the Busselton Health Study.

Authors:  Yi X Chan; Matthew W Knuiman; Mark L Divitini; David J Handelsman; John P Beilby; Bu B Yeap
Journal:  Horm Cancer       Date:  2018-08-10       Impact factor: 3.869

9.  Association of sex steroids, gonadotrophins, and their trajectories with clinical cardiovascular disease and all-cause mortality in elderly men from the Framingham Heart Study.

Authors:  Robin Haring; Zhaoyang Teng; Vanessa Xanthakis; Andrea Coviello; Lisa Sullivan; Shalender Bhasin; Joanne M Murabito; Henri Wallaschofski; Ramachandran S Vasan
Journal:  Clin Endocrinol (Oxf)       Date:  2013-04       Impact factor: 3.478

10.  An update on testosterone, HDL and cardiovascular risk in men.

Authors:  Arthi Thirumalai; Katya B Rubinow; Stephanie T Page
Journal:  Clin Lipidol       Date:  2015
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.